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Abstract
Gastric cancer and liver cancer are among the most 
common malignancies and the leading causes of death 
worldwide, due to late detection and high recurrence 
rates. Today, these cancers have a heavy socioeconom-
ic burden, for which a full understanding of their patho-
physiological features is warranted to search for prom-
ising biomarkers and therapeutic targets. Osteopontin 
(OPN) is overexpressed in most patients with gastric 
and liver cancers. Over the past decade, emerging 
evidence has revealed a correlation of OPN level and 
clinicopathological features and prognosis in gastric and 
liver cancers, indicating its potential as an independent 
prognostic indicator in such patients. Functional stud-
ies have verified the potential of OPN knockdown as a 
therapeutic approach in vitro  and in vivo . Furthermore, 
OPN mediates multifaceted roles in the interaction be-
tween cancer cells and the tumor microenvironment, 
in which many details need further exploration. OPN 
signaling results in various functions, including preven-
tion of apoptosis, modulation of angiogenesis, malfunc-
tion of tumor-associated macrophages, degradation 
of extracellular matrix, activation of phosphoinositide 
3-kinase-Akt and nuclear factor-κB pathways, which 
lead to tumor formation and progression, particularly in 
gastric and liver cancers. This editorial aims to review 
recent findings on alteration in OPN expression and its 
clinicopathological associations with tumor progres-
sion, its potential as a therapeutic target, and putative 
mechanisms in gastric and liver cancers. Better under-
standing of the implications of OPN in tumorigenesis 
might facilitate development of therapeutic regimens to 
benefit patients with these deadly malignancies.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Gastric and liver cancers are among the most common 
malignancies and leading causes of  death worldwide, 
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which carries a heavy socioeconomic burden. Until now, 
surgical resection has remained the frontline treatment for 
patients with early stage gastric and liver cancers. Never-
theless, the majority of  such patients have poor prognosis 
due to high rates of  tumor recurrence as well as lymph 
node (LN) and systemic metastases. Therefore, a full 
understanding of  gastric and liver cancers is crucial to de-
velop useful prognostic markers and therapeutic targets. 
During the past decade, emerging evidence has refined 
the value of  osteopontin (OPN) as a candidate biomarker 
and target for cancer therapy[1]. OPN is a secretory extra-
cellular matrix (ECM) protein that is involved in a series 
of  physiological and pathophysiological processes includ-
ing but not limited to cell attachment, migration, invasion, 
proliferation, tissue remodeling, bone formation and even 
inflammation[1-4]. OPN is frequently overexpressed in 
human cancers and contributes to tumor formation and 
progression[5,6]. OPN belongs to the small integrin bind-
ing ligand N-linked glycoprotein family, which consists 
of  members serving as markers of  early cancer progres-
sion, due to their capabilities in modulating the activity of  
matrix metalloproteinases (MMPs)[7]. OPN participates in 
the interactions between cancer cells and tumor stroma, 
which plays a pivotal role in malignant cancer phenotype. 
A more thorough understanding of  the functional role 
of  OPN in the tumor microenvironment is warranted. 
There have been many reports on OPN and gastric and 
liver cancers, therefore, this review aims to summarize 
recent findings on clinical implications of  OPN, its po-
tential as a therapeutic target, and its related mechanisms 
in these two types of  cancer. Further understanding on 
the role of  OPN in gastric and liver cancers may facilitate 
development of  therapeutic strategies in such patients.
OPN geNe aND PROTeIN STRUCTURe
OPN is a matrix glycoprotein secreted by a variety of  cell 
types including osteoclasts, endothelial cells, epithelial 
cells, and activated immune cells such as macrophages 
and T cells[8]. It is also known as bone sialoprotein Ⅰ, 
early T lymphocyte activation 1 and secreted phospho-
protein 1[9-11]. Human OPN gene is located on chromo-
some 4q21-q25, spans approximately 11 kb, and consists 
of  seven exons encoding the OPN protein with 314 ami-
no acid residues[12]. It contains several highly conserved 
structural elements, including arginine-glycine-aspartate 
and Ser-Val-Val-Tyr-Gly-Leu-Arg domains for integrin 
binding, a calcium binding site and a heparin binding 
domain for CD44 receptor binding[13] (Figure 1). Alter-
native splicing produces three OPN isoforms, OPN-a, 
OPN-b and OPN-c, which probably display different ex-
pression profiles and functional heterogeneity in a tumor-
specific manner[14,15]. Moreover, OPN protein is subjected 
to a series of  post-translational modifications including 
serine/threonine phosphorylation, glycosylation and ty-
rosine sulfation, resulting in molecular variants ranging 
from 25 to 75 kDa[16]. These modifications are cell type 
specific and depend on physiological and pathophysi-
ological factors, which likely affect both OPN structure 
and functions[17].
OPN OveRexPReSSION aND CLINICaL 
vaLUe IN PaTIeNTS wITh gaSTRIC 
CaNCeR
OPN expression is significantly elevated in most gastric 
cancer patients at both transcriptional and translational 
levels[18-24]. OPN protein is overexpressed in both primary 
gastric cancer and metastatic lesions, mildly expressed in 
the epithelial cells in chronic atrophic gastritis that is a 
precancerous lesion for gastric cancer, and negatively in 
normal gastric mucosa, which indicates that OPN may 
play a role and serve as a potential biomarker in the for-
mation and progression of  gastric cancer[18-20]. Moreover, 
Wu et al[19] have found higher OPN plasma level in gastric 
cancer patients as compared with healthy individuals, sug-
gesting that OPN plasma level may also be a biomarker 
for gastric cancer, and is of  particular clinical interest 
because plasma-derived biomarkers are more convenient 
in clinical application than biomarkers from tissues. In 
gastric cancer tissues, OPN protein is diffusely located in 
the cytoplasm of  tumor cells as well as tumor-associated 
macrophages (TAMs), which is in line with its implica-
tions in the interactions between cancer cells and tumor 
stroma.
Until now, the diagnostic and prognostic values of  
OPN have been implicated in gastric cancer patients. 
Microarray studies have identified gene signatures includ-
ing OPN in gastric cancer patients[18]. OPN overexpres-
sion is significantly associated with clinicopathological 
parameters in gastric cancer such as low apoptotic index, 
high proliferative index, low grade, high stage, LN and 
vascular invasion, and distant metastasis[20-24]. In addition, 
OPN overexpression is an independent predictor of  poor 
prognosis and tumor recurrence in patients with gastric 
cancer[21,22]. Dai et al[22] have suggested that patients with 
OPN-positive gastric cancer have poorer outcome than 
OPN-negative cases. Multivariate analysis has revealed 
OPN expression as an independent prognostic indicator 
of  poor disease-free and overall survival in patients with 
gastric cancer, particularly for survival in cases in tumor, 
node, metastasis (TNM) stage Ⅱ and Ⅲ. The prognostic 
value of  the marker combinations of  OPN with conven-
tional biomarkers has also been explored in gastric cancer 
patients. Zhang et al[24] have found the combination of  
OPN and caudal-related homeobox gene 2 (CDX2) as 
a survival predictor of  advanced gastric cancer patients. 
OPN plasma level is commonly elevated in patients with 
gastric cancer, and is significantly associated with the clin-
icopathological features including late stage, serosal inva-
sion, LN and vascular invasion, and liver metastasis[19]. 
High OPN plasma level is inversely correlated with poor 
prognosis in gastric cancer patients, especially in those 
with invasive phenotypes. Thus, elevated OPN plasma 
level may serve as an independent risk factor for poor 
survival in gastric cancer patients. 
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OPN OveRexPReSSION aND CLINICaL 
vaLUe IN PaTIeNTS wITh LIveR CaNCeR
OPN is positive in most hepatocellular carcinoma (HCC) 
patients at both transcriptional and translational lev-
els[25-35]. Yuan et al[28] demonstrated OPN mRNA overex-
pression in 79 (51%) of  156 primary HCC patients. Kim 
et al[35] disclosed that OPN protein was expressed in 92 
(32.3%) of  285 tumors. The expressions of  OPN mRNA 
and protein display a positive correlation[29]. In HCC, 
OPN is secreted by both cancer cells and TAMs, and 
secreted by bile duct epithelium and stellate cells, but not 
by normal hepatocytes or Kupffer cells, in normal liver 
conditions[34,35]. OPN+ cancer cells are often dispersed 
in the periphery of  cancer nodules and are adjacent to 
stromal cells[34,35]. In addition, OPN plasma level is also 
significantly elevated in HCC patients, especially in those 
with cirrhosis or in advanced stages[35-39]. Kim et al[35] 
determined that OPN plasma level in HCC patients was 
significantly higher than in patients with chronic liver 
diseases or healthy controls (954 ng/mL vs 381 ng/mL; 
954 ng/mL vs 155 ng/mL). Zhang et al[36] also found that 
OPN plasma level of  HCC patients was significantly 
higher than that of  healthy controls (176.90 ng/mL vs 
63.74 ng/mL). These data propose that elevated OPN 
plasma level can serve as a potential biomarker for HCC. 
Meanwhile, several microarray studies have identified 
OPN-containing gene signatures of  HCC patients[30-32]. 
Ye et al[31] have identified OPN as a leading gene in the 
gene signature that was relevant to tumor metastasis 
and patient survival. Luo et al[32] have found that overex-
pressed OPN gene belongs to a specific gene signature 
in HCC. In addition, many studies have established a 
significant correlation between OPN overexpression and 
clinicopathological features of  HCC, including the sever-
ity of  liver damage according to Child-Pugh class, high 
grade, late stage, LN/vascular/bile duct/capsular inva-
sion, and intrahepatic or distant metastases[26-30,40-44]. Until 
now, OPN overexpression has been revealed as an inde-
pendent prognostic factor for poor overall and disease-
free survival in HCC patients[25-28,33,42-47]. In 2010, Weber 
et al[42] performed a meta-analysis and found that OPN 
level correlated with poor overall and disease-/relapse-
free survival, and as a biomarker for stage, grade, and 
early tumor progression in HCC. Chen et al[25] disclosed 
that OPN expression was a prognostic marker for HCC 
patients at TNM stage Ⅰ. Furthermore, novel biomarker 
combinations are evaluated to predict patient outcome 
in HCC, since classical parameters cannot provide exact 
information. The biomarker combinations, OPN and 
α-fetoprotein (AFP), or OPN and CD44s, are revealed to 
have better prognostic value than the classical diagnostic 
biomarkers[29,44]. Huang et al[48] have suggested that the 
combination of  OPN and caspase-3 can be an effective 
indicator for HCC patients after curative resection. How-
ever, because the published data are conflicting in many 
cases, further large-scale studies are necessary to confirm 
their clinical value[49].
Tumor recurrence is a persistent issue after surgical 
resection. A number of  studies have suggested OPN as 
a useful marker for predicting early recurrence in HCC 
patients[25-27,33,44-46,50]. OPN polymorphisms and the com-
bination of  OPN and CD44 are potential predictors 
of  tumor recurrence in HCC[45,46]. OPN overexpression 
is associated with early recurrence of  hepatitis C virus 
(HCV)-related HCC[50]. Chen et al[25] found that OPN 
expression was correlated with early postoperative recur-
rence in patients at stage Ⅰ. Sieghart et al[33] have revealed 
that OPN is an independent predictor of  tumor recur-
rence and survival in HCC patients beyond Milan criteria 
undergoing orthotopic liver transplantation. Thus, OPN 
may be able to help determine the patients who need 
adjuvant therapy to prevent early recurrence after surgical 
resection.
At present, many serum biomarkers are under evalu-
ation for the detection of  HCC, but none of  them has 
sufficient sensitivity and specificity to be considered in 
the guidelines. OPN plasma level increases significantly 
with advanced Child-Pugh class, large tumor size, high 
grade, and late stage[35,38]. OPN plasma level is suggested 
as an adverse prognostic factor for both overall survival, 
disease-free survival and relapse-free survival in hepatitis 
Figure 1  Structural features of osteopontin isoforms. Three isoforms of osteopontin (OPN), OPN-a, OPN-b and OPN-c, are known. All of them possess identical 
domains [aspartate domain, arginine-glycine-aspartate domain, Ser-Val-Val-Tyr-Gly-Leu-Arg (SVVYGLR) domain, thrombin cleavage domain, calcium binding domain 
and heparin binding domain] that are linked together with various linkers. These isoforms distinguish themselves by having a variable length of the linker between signal 
peptide and aspartate domain. RGD: Arginine-glycine-aspartate.
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B virus (HBV)- or HCV-related HCC patients[36,38,51]. In 
addition, OPN plasma level may be a potential diagnos-
tic biomarker for HCC in the surveillance of  patients 
with HBV or HCV infection. Sun et al[51] have suggested 
that preoperative plasma level of  OPN and AFP can be 
used as a prognostic marker for early stage HCC. A re-
cent study conducted by Shang et al[52] has also identified 
serum OPN as a novel marker for early HCC diagnosis 
because OPN was found clearly elevated 1 year before di-
agnosis in a pilot prospective study including 22 patients. 
In another two studies, a greater area under curve value 
of  OPN than AFP was observed, suggesting superior 
diagnostic accuracy of  OPN for HCC[38]. HCC patients 
whose pretreatment OPN serum level is low and declines 
following transarterial chemoembolization exhibit better 
tumor response and longer survival[37]. These data suggest 
that OPN plasma level can be used, either independently 
or coupled with AFP, for predicting clinical outcome in 
HCC patients. 
OPN aS a POTeNTIaL TheRaPeUTIC 
TaRgeT FOR gaSTRIC aND LIveR 
CaNCeRS
OPN as a therapeutic target has been explored in various 
tumors including cancers of  breast, lung, head and neck, 
stomach, colon and liver. Promising results have been 
achieved in a series of  studies[53-57]. The strategies often 
utilize OPN antibody to block its binding to receptors so 
as to inhibit the downstream signal transduction related 
to tumor growth and invasion, and deliver the small in-
terfering RNA (siRNA) targeting OPN to tumor cells to 
decrease directly the expression of  OPN to abrogate the 
effects triggered by elevated OPN.
At present, OPN-knockdown-induced tumor sup-
pression in gastric cancer has been shown through RNA 
interference (RNAi)[58-60]. In vitro and in vivo studies have 
demonstrated OPN-RNAi-induced inhibition of  tumor 
growth, migration and invasion in gastric cancer[58,59]. 
Moreover, Wang et al[60] silenced OPN expression in gas-
tric cancer cell line SGC7901 using lentiviral-OPN siRNA 
technology, and found reduced detectable tumors, fewer 
metastases, and longer survival time in mice implanted 
with OPN-SGC7901 cells. These data suggest that target-
ing OPN and its related signaling network is likely to pro-
vide an effective therapeutic approach for gastric cancer 
(Table 1). 
In recent years, efforts have also been made to inhibit 
HCC progression and metastasis by interfering OPN[27,31,61-63]. 
OPN knockdown significantly suppresses migration and 
invasion of  HCC cells in vitro and decreases lung metas-
tases in vivo, which is associated with decreased angiogen-
esis in HCC cells[61,62]. Besides, OPN-specific antibody 
can effectively block HCC cell invasion in vitro and inhibit 
lung metastasis of  HCC cells in vivo[31]. In addition, Zhao 
et al[63] have demonstrated that short hairpin RNA-medi-
ated OPN depletion enhances sensitivity of  HCC cells 
Table 1  Osteopontin as a potential therapeutic target for gastric and liver cancers
Cell lines Mouse model Method of study Resultant effects Possible mechanisms
Gastric cancer
   SGC7901 Nude mice siRNA knockdown Reduced angiogenesis in vitro and in vivo Decreasing microvessel 
density
   BGC-823 Nude mice Transient/stable 
siRNA knockdown
Inhibited cell growth, anchorage-
independent growth, migration and 
invasion in vitro, and suppressed tumor 
growth and prolonged survival in vivo
Inhibition of MMP-2 and 
uPA expression, NF-κB 
DNA binding activity, and 
Akt phosphorylation
   SGC7901 Nude mice implanted 
with SGC-OPN-cells
Lentivirus-mediated 
stable depletion
Suppressed metastases and prolonged 
survival time in vivo
Reducing expression of 
VEGF
HCC
   MHCC97-L,
   MHCC97-H, HCC-LM3
siRNA knockdown Decreased cell invasion and cell cloning 
number in vitro
   HuH1/4/7, MHCC97, 
   SMMC7721, SK-Hep-1, 
   Hep3B, CCL13, HCCLM3
Nude mice of lung 
metastasis
OPN-neutralizing 
antibody
Blocked invasion of SK-Hep-1 and Hep3B 
cells in vitro, inhibited pulmonary metastasis 
of HCC-LM3 cells in vivo
   HCC-LM6 Nude mice implanted 
with HCC-LM6
Antisense knockdown Suppressed migration and invasion in vitro, 
decreased lung metastases in vivo
Inhibiting MMP-2 and uPA 
expression
   HCC-LM3 Nude mice implanted 
with Lenti OPNi- 
transfected HCC-LM3 
cells
Stable depletion using 
lentiviral vectors 
encoding miRNA 
against OPN
Inhibited both in vitro proliferation, 
invasion and in vivo tumor growth and lung 
metastasis
Inhibiting MAPK and NF-κB 
pathways, and MMP-2 and 
suppressing uPA expression
   HCC-LM3 HepG2 Nude mice shRNA gene silencing Inhibited HCC cell growth, adhesion 
and invasion in vitro, and suppressed 
tumorigenicity and lung metastasis in vivo, 
enhanced sensitivity of HCC cells 
to chemotherapeutic drugs
Suppressing αv, β1, β3 
integrin expression, blocking 
NF-κB activation, inhibiting 
apoptosis
HCC: Hepatocellular carcinoma; OPN: Osteopontin; siRNA: Small interfering RNA; MAPK: Mitogen-activated protein kinase; NF: Nuclear factor; MMP: 
Matrix metalloproteinase; VEGF: Vascular endothelial growth factor; uPA: Urokinase-type plasminogen activator; shRNA: Short hairpin RNA; Akt: Protein 
kinase B; miRNA: microRNA .
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to chemotherapeutic drugs through blockade of  nuclear 
factor (NF)-κB activation. Thus, targeting OPN and its 
related signaling network is likely to help develop novel 
therapeutic regimens for HCC (Table 1).
MOLeCULaR MeChaNISMS OF OPN IN 
gaSTRIC aND LIveR CaNCeRS
The multifunction of  OPN has been revealed in promot-
ing tumor formation and progression (Figure 2). It exerts 
these functions through direct binding to integrin and/or 
CD44. The subsequent activation of  various pathways 
leads to increased malignant phenotype[64,65]. Various 
signaling transduction pathways triggered by OPN mol-
ecule have been reported in different cancer models 
such as breast cancer, melanoma, lung cancer, myeloma, 
prostate cancer and gastrointestinal cancers. The results 
indicated that OPN exerts the tumor-related functions 
through a complicated signaling network[65]. Here, we 
only summarize the reported signaling pathways of  OPN 
relevant to gastric and liver cancers; some of  which are 
commonly overlapped with other cancers, but some are 
specific in these two types of  cancers. It has been sug-
gested that phosphoinositide 3-kinase (PI3-K)/protein 
kinase B (Akt) pathway and hypoxia-inducible factor-1 
are involved in the tumor-promoting function of  OPN, 
which induces pro-survival and anti-apoptosis signaling 
in gastric and liver cancers after the survival pathway is 
activated[63,66]. Mitogen-activated protein kinase pathway 
(MEK/ERK1/2) can also be triggered by OPN protein 
in liver cancer to promote tumor growth and metastasis, 
while the effect can be reversed through OPN knock-
down[62]. The NF-κB pathway is crucial to keep cell sur-
vival through initiating the gene expression of  antiapop-
totic proteins, and is often induced by chemotherapeutic 
drugs and contributes to resistance to chemotherapy[59,62]. 
Relevant tumor-promoting functions of  OPN are found 
to be highly associated with NF-κB pathway activation 
in gastric and liver cancers[59,62,63]. The MMP family is re-
sponsible for ECM degradation and remodeling, which 
play an important role in tumor invasion and metastasis. 
OPN-induced metastasis of  gastrointestinal cancers is 
also involved in several MMP members such as MMP-2, 
MMP-9, MMP-7 and other famous invasion-related pro-
teins such as vascular endothelial growth factor (VEGF) 
and urokinase-type plasminogen activator (uPA)[54,59,62,67,68]. 
Recently, Lee et al[66] illustrated that OPN can enhance the 
survival of  gastric cancer through the interaction with 
CD44 variant isoforms. The underlying mechanism in-
volves Src kinase signaling upon OPN binding to CD44, 
followed by “inside-out” integrin activation. In addition, 
there may be a positive correlation between OPN and 
cyclooxygenase-2 (COX-2). OPN, VEGF and COX-2 
could synergistically induce angiogenesis and metastasis 
in gastric cancer[69]. On the other hand, the antitumor 
activity of  COX-2 inhibitors in intestinal cancer is prob-
ably mediated through downregulation of  OPN, which 
results from blockade of  nuclear receptor subfamily 4, 
group A, member 2 (NR4A2) and Wnt/β-catenin signal-
ing, two important components of  the OPN regulatory 
network[70]. 
Several mechanisms regulating OPN gene expres-
sion have been revealed, but many details remain to be 
elucidated. OPN is a transcriptional target of  aberrant 
Wnt/β-catenin signaling[70-72], and is also regulated by 
other molecules including specificity protein 1, v-ets 
erythroblastosis virus E26 oncogene homolog 1, runt-
related transcription factor 2, v-myb myeloblastosis viral 
oncogene homolog, CDX2, deleted in liver cancer 1, 
late SV40 factor (LSF), epidermal growth factor (EGF), 
NR4A2 and NO[24,73-79]. Interestingly, the activation of  
several downstream targets of  OPN, such as Akt, LSF, 
NO, EGF and thrombin, can enhance OPN expression 
in turn, suggesting a positive feedback regulation of  OPN 
gene expression[68,73,78-82]. Moreover, the modulation of  
OPN mRNA stability also influences OPN expression 
in HCC[83,84]. In addition, miRNA-181a decreased OPN 
expression in HCC cell lines, suggesting that miRNA is 
involved in the regulation of  OPN gene expression[85]. 
Furthermore, the expression of  OPN is also affected by 
COX-2 and 30-kDa Tat-interacting protein[70,86,87]. 
In short, OPN signaling could result in the activation 
of  anti-apoptosis and pro-survival pathways via PI3-K-
Akt and NF-κB signaling molecules, angiogenesis modu-
lation via VEGF induction, ECM degradation via MMPs 
OPN
αVβ3 CD44
Src
PI3-K
Akt
VEGF
COX-2
PIP3
MMPs
uPA
NF-κB
P MAPK
ERM
Angiogenesis
ECM degradation 
and migration
Cell survival and 
proliferation
Figure 2  Molecular mechanisms of osteopontin in gastrointestinal can-
cers. Osteopontin (OPN) signaling leads to gastrointestinal cancer growth and 
metastasis through activation of various pathways, including cell survival and 
proliferation, angiogenesis, and extracellular matrix (ECM) degradation. VEGF: 
Vascular endothelial growth factor; PI3-K: Phosphoinositide 3-kinase; COX-2: 
Cyclooxygenase-2; MAPK: Mitogen-activated protein kinase; NF: Nuclear factor; 
uPA: Urokinase-type plasminogen activator; MMP: Matrix metalloproteinase; 
ERM: Ezrin/radixin/moesin; Akt: Protein kinase B.
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and uPA secretion, leading to tumor growth and metasta-
sis in gastric and liver cancers.
CONCLUSION
OPN overexpression occurs frequently in patients with 
gastric cancer and liver cancer. Previous studies have 
revealed its clinicopathological correlation with tumor 
formation and progression in these two types of  cancer, 
indicating its potential as an independent indicator for 
predicting outcome in such patients. Functional studies 
have shown the potential of  OPN as a therapeutic target 
in gastric and liver cancers both in vitro and in vivo. OPN 
mediates multifaceted roles in the interaction between 
cancer cells and tumor microenvironment, in which many 
details need to be further explored. The various mecha-
nisms of  OPN signaling in gastric and liver cancers in-
cluding evasion of  apoptosis, modulation of  angiogenesis, 
ECM degradation, activation of  PI3-K-Akt and NF-κB 
pathways, might induce the development and progression 
of  gastric and liver cancers. However, no clinical trial tar-
geting OPN is in progress for tumor treatment, although 
the importance of  OPN has been widely investigated 
and demonstrated in various cancers, and many patents 
including antibodies or peptides against OPN have been 
filed to treat different tumors. OPN is an important cyto-
kine to mediate normal physiological functions. Blocking 
OPN possibly results in severe adverse effects due to in-
terference with normal OPN roles. Therefore, further un-
derstanding of  the implications and roles of  OPN in vari-
ous tumors including gastric and liver cancers could help 
develop better therapeutic strategies for such patients. On 
the other hand, OPN as a secreted plasma protein seems 
to have a greater potential to be utilized as a diagnostic or 
prognostic marker for in relevant cancers in combination 
with other biomarkers or alone.
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